CN110669052B - 取代的2-氮杂二环化合物以及它们作为食欲素受体调节剂的用途 - Google Patents

取代的2-氮杂二环化合物以及它们作为食欲素受体调节剂的用途 Download PDF

Info

Publication number
CN110669052B
CN110669052B CN201910948604.1A CN201910948604A CN110669052B CN 110669052 B CN110669052 B CN 110669052B CN 201910948604 A CN201910948604 A CN 201910948604A CN 110669052 B CN110669052 B CN 110669052B
Authority
CN
China
Prior art keywords
azabicyclo
esi
compound
measured value
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910948604.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN110669052A (zh
Inventor
C.F.格林
T.P.勒博德
B.T.斯雷曼
J.M.兹夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN110669052A publication Critical patent/CN110669052A/zh
Application granted granted Critical
Publication of CN110669052B publication Critical patent/CN110669052B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN201910948604.1A 2013-03-13 2014-03-12 取代的2-氮杂二环化合物以及它们作为食欲素受体调节剂的用途 Active CN110669052B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361780378P 2013-03-13 2013-03-13
US61/780378 2013-03-13
PCT/US2014/024293 WO2014165070A1 (en) 2013-03-13 2014-03-12 Substituted 2-azabicycles and their use as orexin receptor modulators
CN201480027437.2A CN105308048B (zh) 2013-03-13 2014-03-12 取代的2-氮杂二环化合物以及它们作为食欲素受体调节剂的用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480027437.2A Division CN105308048B (zh) 2013-03-13 2014-03-12 取代的2-氮杂二环化合物以及它们作为食欲素受体调节剂的用途

Publications (2)

Publication Number Publication Date
CN110669052A CN110669052A (zh) 2020-01-10
CN110669052B true CN110669052B (zh) 2022-10-11

Family

ID=50487148

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201910948604.1A Active CN110669052B (zh) 2013-03-13 2014-03-12 取代的2-氮杂二环化合物以及它们作为食欲素受体调节剂的用途
CN201810842686.7A Pending CN108864093A (zh) 2013-03-13 2014-03-12 取代的2-氮杂二环化合物以及它们作为食欲素受体调节剂的用途
CN201480027437.2A Active CN105308048B (zh) 2013-03-13 2014-03-12 取代的2-氮杂二环化合物以及它们作为食欲素受体调节剂的用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201810842686.7A Pending CN108864093A (zh) 2013-03-13 2014-03-12 取代的2-氮杂二环化合物以及它们作为食欲素受体调节剂的用途
CN201480027437.2A Active CN105308048B (zh) 2013-03-13 2014-03-12 取代的2-氮杂二环化合物以及它们作为食欲素受体调节剂的用途

Country Status (38)

Country Link
US (5) US8969352B2 (https=)
EP (4) EP3622956B9 (https=)
JP (1) JP6275815B2 (https=)
KR (1) KR102209424B1 (https=)
CN (3) CN110669052B (https=)
AR (1) AR095423A1 (https=)
AU (2) AU2014248680B2 (https=)
BR (1) BR112015022294B1 (https=)
CA (1) CA2904618C (https=)
CL (1) CL2015002609A1 (https=)
CR (2) CR20210523A (https=)
CY (3) CY1120024T1 (https=)
DK (2) DK2970314T3 (https=)
EA (1) EA029276B1 (https=)
ES (3) ES2760564T3 (https=)
HR (3) HRP20180303T1 (https=)
HU (3) HUE047592T2 (https=)
IL (2) IL240466B (https=)
JO (1) JOP20140092B1 (https=)
LT (2) LT2970314T (https=)
ME (2) ME03011B (https=)
MX (2) MX361529B (https=)
MY (1) MY183725A (https=)
NI (1) NI201500130A (https=)
NO (1) NO3107630T3 (https=)
PE (1) PE20151599A1 (https=)
PH (1) PH12015501929B1 (https=)
PL (3) PL3363438T3 (https=)
PT (2) PT2970314T (https=)
RS (3) RS64551B9 (https=)
SG (1) SG11201507415QA (https=)
SI (2) SI3363438T1 (https=)
SM (3) SMT201900655T1 (https=)
TW (1) TWI621618B (https=)
UA (1) UA118669C2 (https=)
UY (1) UY35409A (https=)
WO (1) WO2014165070A1 (https=)
ZA (1) ZA201507562B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME03452B (me) 2009-10-23 2020-01-20 Janssen Pharmaceutica Nv Disupstituisani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptora
WO2011090738A2 (en) 2009-12-29 2011-07-28 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US9382239B2 (en) 2011-11-17 2016-07-05 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
TW201444821A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
TWI621618B (zh) * 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
SG11201607183PA (en) 2014-03-06 2016-10-28 Shanghai Haiyan Pharmaceutical Technology Co Ltd Piperidine derivatives as orexin receptor antagonist
KR102455043B1 (ko) * 2014-09-11 2022-10-13 얀센 파마슈티카 엔.브이. 치환된 2-아자바이사이클 및 오렉신 수용체 조절제로서의 이의 용도
WO2016100157A2 (en) * 2014-12-19 2016-06-23 Merck Sharp & Dohme Corp. 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
JP6854762B2 (ja) 2014-12-23 2021-04-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤
USRE50776E1 (en) 2015-03-27 2026-02-03 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US10196383B2 (en) 2015-07-17 2019-02-05 Sunshine Lake Pharma Co., Ltd. Substituted quinazoline compounds and preparation and uses thereof
DK3336088T3 (da) * 2015-08-14 2021-06-28 Shanghai Haiyan Pharmaceutical Tech Co Ltd Krystalform af orexinreceptorantagonistforbindelse, og fremgangsmåde til fremstilling og anvendelse af denne
AU2016319125B2 (en) 2015-09-09 2021-04-08 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
AU2016360245B2 (en) 2015-11-23 2020-07-09 Sunshine Lake Pharma Co., Ltd. Octahydropyrrolo [3, 4-c] pyrrole derivatives and uses thereof
MD3426251T2 (ro) 2016-03-10 2022-09-30 Janssen Pharmaceutica Nv Metode de tratament al depresiei utilizând antagoniști ai receptorului orexină-2
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
NZ748641A (en) 2016-06-13 2020-04-24 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
AU2017363307B2 (en) 2016-11-22 2021-07-29 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof
SI4122464T1 (sl) 2017-03-28 2024-07-31 Gilead Sciences, Inc. Terapevtske kombinacije za zdravljenje bolezni jeter
GB2558975B (en) * 2017-09-01 2019-01-23 Chronos Therapeutics Ltd Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists
KR102858857B1 (ko) * 2017-09-01 2025-09-12 크로노스 테라퓨틱스 리미티드 오렉신 수용체 길항제로서의 치환된 2-아자바이사이클로[3.1.1]헵탄 및 2-아자바이사이클로[3.2.1]옥탄 유도체
EP3810132A4 (en) 2018-06-25 2022-06-22 Dana-Farber Cancer Institute, Inc. TAIRE FAMILY KINASE INHIBITORS AND RELATED USES
US20220073512A1 (en) * 2018-12-14 2022-03-10 Dana-Farber Cancer Institute, Inc. Pyrazolopyridine inhibitors of c-jun-n-terminal kinases and uses thereof
US12281126B2 (en) 2018-12-28 2025-04-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
PT3911647T (pt) 2019-01-15 2024-03-04 Gilead Sciences Inc Composto de isoxazole como agonista de fxr e composições farmacêuticas que o contenham
JP2022519906A (ja) 2019-02-19 2022-03-25 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒアゴニストの固体形態

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008150364A1 (en) * 2007-05-23 2008-12-11 Merck & Co., Inc. Cyclopropyl pyrrolidine orexin receptor antagonists
CN101965343A (zh) * 2008-02-21 2011-02-02 埃科特莱茵药品有限公司 2-氮杂-双环[2.2.1]庚烷衍生物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674793A (en) 1967-03-29 1972-07-04 Sterling Drug Inc 6-hydroxy-2-azabicyclo(2.2.2)octan-3-ones and 2-azabicyclo(2.2.2.)octane-3,6-diones
US6505492B2 (en) 2001-04-11 2003-01-14 Bethlehem Steel Corporation Method and apparatus for forming deep-drawn articles
EP1396488A1 (en) 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
EP1594852A1 (en) 2003-02-07 2005-11-16 Ranbaxy Laboratories, Ltd. Oxazolidinone derivatives as antimicrobials
MXPA05008108A (es) 2003-02-21 2005-09-21 Pharmacia & Upjohn Co Llc Exo-(2r)(+))-2-amino-7-azabiciclo[2.2.1]heptan-7-carboxilato de terc-butilo, compuestos intermedios y procedimiento para prepararlos y aislarlos.
AU2006329007A1 (en) 2005-12-20 2007-06-28 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutamate receptors
JP2010502664A (ja) 2006-09-11 2010-01-28 ノバルティス アクチエンゲゼルシャフト 代謝型グルタミン酸受容体の調節剤としてのニコチン酸誘導体
ES2357992T3 (es) 2006-12-01 2011-05-04 Actelion Pharmaceuticals Ltd. Derivados de 3-heteroaril(amino o amido)-1-(bifenil o feniltiazolil)carbonilpiperidina como inhibidores del receptor de orexina.
TW200833328A (en) 2006-12-28 2008-08-16 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[3.1.0]hexane derivatives
EA016595B1 (ru) 2007-07-17 2012-06-29 Бристол-Маерс Сквибб Компани Способ модулирования рецептора gpr119, сопряженного с g-белком, и используемые при этом соединения
AU2008340421B2 (en) 2007-12-21 2013-12-19 F. Hoffmann-La Roche Ag Heteroaryl derivatives as orexin receptor antagonists
US20110039857A1 (en) 2008-04-30 2011-02-17 Hamed Aissaoui Piperidine and pyroolidine compounds
MX2011000664A (es) 2008-07-16 2011-02-24 Schering Corp Derivados biciclicos heterociclicos y uso de los mismos como moduladores de gpr119.
US8710076B2 (en) 2008-10-21 2014-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
WO2010048016A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,3-disubstituted piperidine orexin receptor antagonists
US20100144760A1 (en) 2008-12-02 2010-06-10 Giuseppe Alvaro Novel compounds
AR076024A1 (es) 2009-04-03 2011-05-11 Schering Corp Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos
EP2421850A1 (en) 2009-04-24 2012-02-29 Glaxo Group Limited 3 -azabicyclo [4.1.0]heptanes used as orexin antagonists
WO2011050202A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
JP5847087B2 (ja) * 2009-10-23 2016-01-20 ヤンセン ファーマシューティカ エヌ．ベー． オレキシン受容体調節因子としての縮合複素環式化合物
ME03452B (me) 2009-10-23 2020-01-20 Janssen Pharmaceutica Nv Disupstituisani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptora
WO2011053688A1 (en) 2009-10-29 2011-05-05 Schering Corporation Bridged bicyclic piperidine derivatives and methods of use thereof
US9301929B2 (en) 2009-11-24 2016-04-05 Merck Sharp & Dohme Corp. Substituted biaryl derivatives and methods of use thereof
US8476295B2 (en) 2009-12-14 2013-07-02 Inspire Bridged bicyclic RHO kinase inhibitor compounds, composition and use
WO2011087812A1 (en) 2009-12-21 2011-07-21 Vanderbilt University Alkyl 3-((2-amidoethyl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate analogs as selective m1 agonists and methods of making and using same
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
US20130096141A1 (en) 2010-06-18 2013-04-18 Bernard R. Neustadt Bicyclic heterocycle derivatives and methods of use thereof
WO2012089606A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists
WO2012145581A1 (en) 2011-04-20 2012-10-26 Janssen Pharmaceutica Nv Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
EP2911675A4 (en) 2012-10-23 2016-06-01 Merck Sharp & Dohme 2-PYRIDYLOXY-3-SUBSTITUTED 4-NITRIL-OREXINE RECEPTOR ANTAGONISTS
BR112015011148A8 (pt) 2012-11-16 2019-10-01 Merck Sharp & Dohme composto, composição farmacêutica, e combinação
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
US9452986B2 (en) 2014-02-06 2016-09-27 Abbvie Inc. 6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use
KR102455043B1 (ko) 2014-09-11 2022-10-13 얀센 파마슈티카 엔.브이. 치환된 2-아자바이사이클 및 오렉신 수용체 조절제로서의 이의 용도

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008150364A1 (en) * 2007-05-23 2008-12-11 Merck & Co., Inc. Cyclopropyl pyrrolidine orexin receptor antagonists
CN101965343A (zh) * 2008-02-21 2011-02-02 埃科特莱茵药品有限公司 2-氮杂-双环[2.2.1]庚烷衍生物

Also Published As

Publication number Publication date
MX368466B (es) 2019-10-03
PH12015501929A1 (en) 2016-01-04
WO2014165070A1 (en) 2014-10-09
ZA201507562B (en) 2019-04-24
AU2014248680B2 (en) 2018-07-26
UY35409A (es) 2014-09-30
ES2760564T3 (es) 2020-05-14
EA201591703A1 (ru) 2016-02-29
HUE047592T2 (hu) 2020-05-28
ME03011B (me) 2018-10-20
LT3363438T (lt) 2019-11-11
EP3363438A1 (en) 2018-08-22
HRP20192032T1 (hr) 2020-02-07
US9447117B2 (en) 2016-09-20
LT2970314T (lt) 2018-02-12
US20170204096A1 (en) 2017-07-20
CN110669052A (zh) 2020-01-10
EP3622956A1 (en) 2020-03-18
CN108864093A (zh) 2018-11-23
EP3622956B1 (en) 2023-06-07
CA2904618A1 (en) 2014-10-09
NZ710872A (en) 2020-10-30
JP2016512535A (ja) 2016-04-28
NI201500130A (es) 2015-11-30
PL3622956T3 (pl) 2023-09-18
DK2970314T3 (en) 2018-02-26
CN105308048B (zh) 2019-10-08
SG11201507415QA (en) 2015-10-29
CY1122392T1 (el) 2021-01-27
DK3363438T3 (da) 2019-11-11
HUE036193T2 (hu) 2018-06-28
RS64551B9 (sr) 2023-12-29
CY1120024T1 (el) 2018-12-12
HUE063608T2 (hu) 2024-01-28
IL240466A0 (en) 2015-09-24
JP6275815B2 (ja) 2018-02-07
MY183725A (en) 2021-03-10
RS59466B1 (sr) 2019-11-29
HRP20180303T1 (hr) 2018-03-23
CY1126106T1 (el) 2023-11-15
PE20151599A1 (es) 2015-11-12
PL2970314T3 (pl) 2018-05-30
TW201446757A (zh) 2014-12-16
SMT201800056T1 (it) 2018-03-08
AR095423A1 (es) 2015-10-14
PT3363438T (pt) 2019-12-11
MX2015011815A (es) 2016-11-07
US9845333B2 (en) 2017-12-19
SMT201900655T1 (it) 2020-01-14
EP3622956C0 (en) 2023-06-07
TWI621618B (zh) 2018-04-21
PL3363438T3 (pl) 2020-02-28
US20150174129A1 (en) 2015-06-25
US20160052939A1 (en) 2016-02-25
UA118669C2 (uk) 2019-02-25
IL264606A (en) 2019-02-28
RS64551B1 (sr) 2023-10-31
EA029276B1 (ru) 2018-03-30
NO3107630T3 (https=) 2018-01-06
AU2018204835A1 (en) 2018-07-19
HRP20230633T1 (hr) 2023-09-29
CA2904618C (en) 2021-12-07
CL2015002609A1 (es) 2016-03-28
CR20210523A (es) 2021-11-19
HK1219725A1 (en) 2017-04-13
EP3363438B1 (en) 2019-09-18
US8969352B2 (en) 2015-03-03
US20140275118A1 (en) 2014-09-18
BR112015022294A2 (pt) 2017-07-18
KR20150126694A (ko) 2015-11-12
SMT202300223T1 (it) 2023-09-06
MX361529B (es) 2018-12-07
BR112015022294B1 (pt) 2022-09-13
JOP20140092B1 (ar) 2021-08-17
US20170015651A1 (en) 2017-01-19
PH12015501929B1 (en) 2016-01-04
EP4272824A3 (en) 2024-01-10
ME03572B (me) 2020-07-20
US9611277B2 (en) 2017-04-04
PT2970314T (pt) 2018-03-05
KR102209424B1 (ko) 2021-01-29
ES2950032T3 (es) 2023-10-04
SI3363438T1 (sl) 2019-11-29
AU2018204835B2 (en) 2019-08-08
CR20150433A (es) 2015-10-26
IL240466B (en) 2019-03-31
EP2970314A1 (en) 2016-01-20
EP4272824A2 (en) 2023-11-08
EP2970314B1 (en) 2017-12-13
CN105308048A (zh) 2016-02-03
ES2659397T3 (es) 2018-03-15
SI2970314T1 (en) 2018-02-28
EP3622956B9 (en) 2023-09-27
AU2014248680A1 (en) 2015-08-27
RS56875B1 (sr) 2018-04-30
US10183953B2 (en) 2019-01-22

Similar Documents

Publication Publication Date Title
CN110669052B (zh) 取代的2-氮杂二环化合物以及它们作为食欲素受体调节剂的用途
KR102209432B1 (ko) 치환된 7-아자바이사이클 및 오렉신 수용체 조절제로서의 이의 용도
CN105228995A (zh) 取代的哌啶化合物以及它们作为食欲素受体调节剂的用途
BR112017004742B1 (pt) 2-azabiciclos substituídos e seu uso como moduladores de receptor de orexina
HK40020928B (en) Substituted 2-azabicycles and their use as orexin receptor modulators
HK40020928A (en) Substituted 2-azabicycles and their use as orexin receptor modulators
HK1261216A1 (en) Substituted 2-azabicycles and their use as orexin receptor modulators
NZ793902A (en) Substituted 2-azabicycles and their use as orexin receptor modulators
HK40025557A (en) Substituted 2-azabicycles and their use as orexin receptor modulators
NZ710872B2 (en) Substituted 2-azabicycles and their use as orexin receptor modulators
HK1219725B (en) Substituted 2-azabicycles and their use as orexin receptor modulators

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40020928

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant